Program

Invited Lecture

Day 3, May 17（Thu.）　15:25-15:55　Room A (OrBit Hall)

3A-IL-K-1525　　PDF

Lung Cancer Biomarkers by MS-Proteomics and Validation by Diagnostic Assay

(¹SNU, ²SMC, ³CNU)
Hye-jin Sung¹, Yong-in Kim¹, Jung-mo Ahn¹, Soo-youn Lee², Hyun-joo An³, ^oJe-yoel Cho¹

Without any effective tool for screening and early diagnosis, lung cancer shows the highest mortality in cancer related death. Here, we show the development of lung cancer proteome biomarkers and clinical assay. By LC-ms/ms–based proteomics approaches combined with glycoprotein or low molecular weight protein enrichment technologies in the sera of the cancer patients, we discovered several potential lung cancer protein biomarkers. iTRAQ and label-free quantitative proteomics combined with fucosylated glycoprotein enrichment approaches also revealed that not only the amount of the glycoprotein biomarkers but also their fucosylation levels and patterns can serve as diagnostic and prognostic serological markers for lung cancers. These biomarkers were validated by immunoassays and lectin-hybrid ELISA. Functional analysis also revealed that a biomarker PON1 promoted ROS deregulation protecting the mitochondria from dysregulation. We also showed multiple reaction monitoring (MRM) for the quantitative measurement of our lung cancer biomarkers developed by mass spectrometry in the sera of the patients. Then, we pursued to develop a pair of target specific monoclonal antibodies which can be used for the pair-test ELISA and Rapid kit assay development. The rapid kit was used for the test of the sera from lung cancer patients. We are currently applying multiple biomarkers to the assay kit to improve the specificity and sensitivity for the diagnosis of lung cancers.